Sign in or create an account to add this stock to your watchlist.
About Jounce Therapeutics (NASDAQ:JNCE)
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840
Debt
Debt-to-Equity RatioN/A
Current Ratio3.63
Quick Ratio3.63
Price-To-Earnings
Trailing P/E Ratio-18.26
Forward P/E Ratio-9.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.64 million
Price / Sales4.97
Cash FlowN/A
Price / CashN/A
Book Value$5.18 per share
Price / Book2.12
Profitability
EPS (Most Recent Fiscal Year)($0.57)
Net Income$-16,440,000.00
Net Margins-47.73%
Return on Equity-19.90%
Return on Assets-10.22%
Miscellaneous
Employees112
Outstanding Shares32,480,000
Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions
What is Jounce Therapeutics' stock symbol?
Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."
How were Jounce Therapeutics' earnings last quarter?
Jounce Therapeutics (NASDAQ:JNCE) posted its earnings results on Wednesday, May, 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.09. The company had revenue of $11.20 million for the quarter, compared to analyst estimates of $13.33 million. Jounce Therapeutics had a negative return on equity of 19.90% and a negative net margin of 47.73%. View Jounce Therapeutics' Earnings History.
When is Jounce Therapeutics' next earnings date?
What price target have analysts set for JNCE?
5 Wall Street analysts have issued 12 month price targets for Jounce Therapeutics' stock. Their forecasts range from $13.00 to $35.00. On average, they anticipate Jounce Therapeutics' share price to reach $23.75 in the next twelve months. View Analyst Ratings for Jounce Therapeutics.
Who are some of Jounce Therapeutics' key competitors?
Some companies that are related to Jounce Therapeutics include DBV Technologies (DBVT), Audentes Therapeutics (BOLD), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), Coherus BioSciences (CHRS), La Jolla Pharmaceutical (LJPC), Solid Biosciences (SLDB), Heska (HSKA), Novavax (NVAX), CASI Pharmaceuticals (CASI), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX) and Fate Therapeutics (FATE).
Who are Jounce Therapeutics' key executives?
Jounce Therapeutics' management team includes the folowing people:
- Dr. Richard Murray, Pres, CEO & Director (Age 59)
- Ms. Kimberlee Cobleigh Drapkin, CFO, Treasurer & Principal Accounting Officer (Age 50)
- Dr. Elizabeth G. Trehu M.D., Chief Medical Officer (Age 58)
- Dr. James P. Allison Ph.D., Founder
- Dr. Thomas F. Gajewski M.D., Ph.D., Founder
When did Jounce Therapeutics IPO?
(JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.
Has Jounce Therapeutics been receiving favorable news coverage?
Headlines about JNCE stock have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Jounce Therapeutics earned a news impact score of 0.15 on Accern's scale. They also gave news headlines about the company an impact score of 47.36 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Jounce Therapeutics' major shareholders?
Jounce Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (3.64%), BlackRock Inc. (3.52%), Omega Fund Management LLC (1.63%), venBio Select Advisor LLC (1.61%), Citadel Advisors LLC (0.90%) and Fosun International Ltd (0.49%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Celgene Switzerland Llc, Elizabeth Trehu, John Duncan Higgons, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.
Which institutional investors are selling Jounce Therapeutics stock?
JNCE stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Spark Investment Management LLC, Omega Fund Management LLC, Parsons Capital Management Inc. RI, Parsons Capital Management Inc. RI, BlackRock Inc., Russell Investments Group Ltd. and Northern Trust Corp. Company insiders that have sold Jounce Therapeutics company stock in the last year include Barbara Gayle Duncan, Elizabeth Trehu, Kimberlee C Drapkin and Richard /Ca/ Murray. View Insider Buying and Selling for Jounce Therapeutics.
Which institutional investors are buying Jounce Therapeutics stock?
JNCE stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Citadel Advisors LLC, Redmile Group LLC, Elephas Investment Management Ltd, Dimensional Fund Advisors LP, A.R.T. Advisors LLC, JBF Capital Inc. and Cubist Systematic Strategies LLC. Company insiders that have bought Jounce Therapeutics stock in the last two years include Celgene Switzerland Llc and John Duncan Higgons. View Insider Buying and Selling for Jounce Therapeutics.
How do I buy shares of Jounce Therapeutics?
Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jounce Therapeutics' stock price today?
One share of JNCE stock can currently be purchased for approximately $10.82.
How big of a company is Jounce Therapeutics?
Jounce Therapeutics has a market capitalization of $369.34 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.
How can I contact Jounce Therapeutics?
Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.
MarketBeat Community Rating for Jounce Therapeutics (JNCE)
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Jounce Therapeutics (NASDAQ:JNCE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Jounce Therapeutics in the last 12 months. Their average twelve-month price target is $23.75, suggesting that the stock has a possible upside of 116.70%. The high price target for JNCE is $35.00 and the low price target for JNCE is $13.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.80 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $23.75 | $31.50 | $29.00 | $29.00 |
| Price Target Upside: | 116.70% upside | 20.78% upside | 95.81% upside | 95.81% upside |
Jounce Therapeutics (NASDAQ:JNCE) Consensus Price Target History
Jounce Therapeutics (NASDAQ:JNCE) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Jounce Therapeutics (NASDAQ:JNCE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Jounce Therapeutics (NASDAQ JNCE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 43.97%
Institutional Ownership Percentage: 91.15%
Jounce Therapeutics (NASDAQ JNCE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/15/2018 | Barbara Gayle Duncan | Director | Sell | 2,000 | $28.11 | $56,220.00 | 2,000 |  |
| 3/8/2018 | Elizabeth Trehu | Insider | Sell | 4,545 | $25.06 | $113,897.70 | 4,545 | |
| 3/8/2018 | Kimberlee C Drapkin | CFO | Sell | 5,267 | $25.01 | $131,727.67 | 5,267 | |
| 3/8/2018 | Richard /Ca/ Murray | CEO | Sell | 16,334 | $25.10 | $409,983.40 | 16,334 | |
| 3/5/2018 | Elizabeth Trehu | Insider | Sell | 4,545 | $21.50 | $97,717.50 | 4,545 | |
| 3/5/2018 | Kimberlee C Drapkin | CFO | Sell | 5,267 | $21.42 | $112,819.14 | 2,775 | |
| 3/5/2018 | Richard /Ca/ Murray | CEO | Sell | 16,334 | $21.43 | $350,037.62 | 16,334 | |
| 1/26/2018 | Barbara Gayle Duncan | Director | Sell | 4,000 | $25.00 | $100,000.00 | 4,000 | |
| 2/1/2017 | Celgene Switzerland Llc | Major Shareholder | Buy | 625,000 | $16.00 | $10,000,000.00 | | |
| 2/1/2017 | John Duncan Higgons | Director | Buy | 6,700 | $16.00 | $107,200.00 | 27,025 | |
(Data available from 1/1/2013 forward)
Jounce Therapeutics (NASDAQ JNCE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Why J.C. Penney, NetEase, and Jounce Therapeutics Slumped Today
finance.yahoo.com - May 18 at 10:29 AM |
| Jounce Therapeutics Gets Throttled, Loses 35% Today
finance.yahoo.com - May 18 at 10:29 AM |
 | Jounce Therapeutics (JNCE) to Present Data from Ongoing ICONIC Trial of JTX-2011 at ASCO
www.streetinsider.com - May 17 at 4:40 PM |
 | Why Jounce Shares Are Crumbling Ahead of ASCO
247wallst.com - May 17 at 4:40 PM |
 | Jounce Therapeutics (JNCE) Given a $19.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 17 at 2:59 PM |
| Wells Fargo Downgrades Jounce Therapeutics (JNCE) to Market Perform
www.americanbankingnews.com - May 17 at 2:54 PM |
| Jounce Therapeutics (JNCE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 17 at 10:00 AM |
 | Jounce down 32% premarket on announcement of trial data on lead candidate JTX-2011
seekingalpha.com - May 17 at 9:21 AM |
| Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 9:21 AM |
| Analysts Expect Jounce Therapeutics (JNCE) Will Announce Quarterly Sales of $13.50 Million
www.americanbankingnews.com - May 14 at 2:51 AM |
| Zacks Investment Research Lowers Jounce Therapeutics (JNCE) to Sell
www.americanbankingnews.com - May 12 at 5:01 PM |
| -$0.38 EPS Expected for Jounce Therapeutics (JNCE) This Quarter
www.americanbankingnews.com - May 12 at 3:19 PM |
| Traders Purchase High Volume of Call Options on Jounce Therapeutics (JNCE)
www.americanbankingnews.com - May 11 at 8:15 AM |
| Jounce Therapeutics Target of Unusually Large Options Trading (JNCE)
www.americanbankingnews.com - May 11 at 7:18 AM |
| Jounce Therapeutics (JNCE) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - May 10 at 9:52 PM |
| HC Wainwright Reiterates $33.00 Price Target for Jounce Therapeutics (JNCE)
www.americanbankingnews.com - May 10 at 7:05 PM |
| Edited Transcript of JNCE.O earnings conference call or presentation 9-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 9:27 AM |
| Jounce Therapeutics' (JNCE) CEO Rich Murray on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:43 PM |
| Jounce Therapeutics misses by $0.09, misses on revenue
seekingalpha.com - May 9 at 9:14 AM |
| Jounce Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 9:14 AM |
| Zacks: Jounce Therapeutics (JNCE) Given $33.25 Consensus Price Target by Brokerages
www.americanbankingnews.com - May 8 at 11:43 AM |
| Jounce Therapeutics (JNCE) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - April 27 at 9:27 AM |
| $13.50 Million in Sales Expected for Jounce Therapeutics (JNCE) This Quarter
www.americanbankingnews.com - April 27 at 5:28 AM |
| -$0.31 EPS Expected for Jounce Therapeutics (JNCE) This Quarter
www.americanbankingnews.com - April 25 at 3:24 AM |
| Zacks: Brokerages Set $33.33 Target Price for Jounce Therapeutics (JNCE)
www.americanbankingnews.com - April 23 at 5:14 AM |
| Jounce Therapeutics (JNCE) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:16 PM |
| Jounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 12 at 10:02 AM |
| Jounce Therapeutics (JNCE) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:11 PM |
| Brokerages Anticipate Jounce Therapeutics (JNCE) Will Post Quarterly Sales of $13.50 Million
www.americanbankingnews.com - April 10 at 4:30 AM |
| Agios and Jounce spike on potential Celgene interest
seekingalpha.com - April 9 at 4:43 PM |
| Jounce Therapeutics (JNCE) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - April 8 at 3:18 AM |
| Jounce Therapeutics (JNCE) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:14 PM |
| Analysts Anticipate Jounce Therapeutics (JNCE) to Post ($0.31) Earnings Per Share
www.americanbankingnews.com - April 7 at 9:55 AM |
| Jounce Therapeutics (JNCE) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:42 PM |
| Jounce Therapeutics Inc (JNCE) Expected to Post Quarterly Sales of $13.50 Million
www.americanbankingnews.com - March 24 at 8:52 AM |
| Zacks: Jounce Therapeutics Inc (JNCE) Given $33.33 Average Price Target by Brokerages
www.americanbankingnews.com - March 23 at 1:16 AM |
| Jounce Therapeutics Inc (JNCE) Director Sells $56,220.00 in Stock
www.americanbankingnews.com - March 19 at 8:28 PM |
| Jounce Therapeutics (JNCE) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 18 at 11:17 AM |
| Contrasting Jounce Therapeutics (JNCE) & Ultragenyx Pharmaceutical (RARE)
www.americanbankingnews.com - March 14 at 12:34 PM |
 | Charting the market recovery, Nasdaq takes flight as Dow industrials diverge
www.marketwatch.com - March 14 at 12:16 PM |
| Jounce Therapeutics Inc (JNCE) Insider Elizabeth Trehu Sells 4,545 Shares
www.americanbankingnews.com - March 12 at 10:26 PM |
| Jounce Therapeutics Inc (JNCE) CFO Sells $131,727.67 in Stock
www.americanbankingnews.com - March 12 at 7:57 PM |
| Insider Selling: Jounce Therapeutics Inc (JNCE) CEO Sells 16,334 Shares of Stock
www.americanbankingnews.com - March 12 at 7:38 PM |
| Jounce Therapeutics (JNCE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 11 at 4:06 PM |
| Robert W. Baird Reiterates $35.00 Price Target for Jounce Therapeutics (JNCE)
www.americanbankingnews.com - March 8 at 7:21 PM |
| Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 10:30 AM |
| Jounce Therapeutics (JNCE) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - March 8 at 9:16 AM |
| Jounce Therapeutics Inc (JNCE) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 8 at 3:12 AM |
| Insider Selling: Jounce Therapeutics Inc (JNCE) CFO Sells 5,267 Shares of Stock
www.americanbankingnews.com - March 8 at 12:46 AM |
| Insider Selling: Jounce Therapeutics Inc (JNCE) Insider Sells 4,545 Shares of Stock
www.americanbankingnews.com - March 8 at 12:46 AM |
Jounce Therapeutics (NASDAQ:JNCE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Jounce Therapeutics (NASDAQ:JNCE) Income Statement, Balance Sheet and Cash Flow Statement
Jounce Therapeutics (NASDAQ JNCE) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
